Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04086329 · ClinicalTrials.gov registry record · Phase 1
Validation of Oxygen Nanosensor in Mitochondrial Myopathy
A Phase 1 study of Mitochondrial Diseases and MItochondrial Myopathies, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04086329 is a Phase 1 study of Mitochondrial Diseases and MItochondrial Myopathies that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 24 participants, below the 273-participant average among 7 other Mitochondrial Diseases trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04086329, a Phase 1 study of Mitochondrial Diseases and MItochondrial Myopathies, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Past mitochondrial disease treatment studies have been unsuccessful in determining treatment efficacy, and a major factor has been the lack of validated biomarkers in mitochondrial myopathy (MM). There is currently a growing number of potential new treatments to be tested through MM clinical intervention trials, which has created a pressing need for quantitative biomarkers that reliably reflect MM disease severity, progression, and therapeutic response. The purpose of the study is to measure the efficacy of an electrochemical oxygen nanosensor to measure in vivo mitochondrial function in human muscle tissue, and its ability to discriminate MM patients from healthy volunteers. The data and results from this nanosensor study may contribute to current and future research, including improved diagnostic and therapeutic approaches for patients with mitochondrial disease.
Conditions Studied
Interventions
- DEVICE Nanosensor
Study Locations (1)
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04086329
The ClinicalTrials.gov registry entry for NCT04086329 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 273-participant average among 7 other Mitochondrial Diseases trials with a reported enrollment target (91% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mitochondrial Diseases appearing as the primary indexed condition, and to 1 intervention - of which Nanosensor is the first listed.
NCT04086329 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04086329 about?
NCT04086329 is a clinical study titled "Validation of Oxygen Nanosensor in Mitochondrial Myopathy". Past mitochondrial disease treatment studies have been unsuccessful in determining treatment efficacy, and a major factor has been the lack of validated biomarkers in mitochondrial myopathy (MM). There is currently a growing number of potential new treatments to be tested through MM clinical interve...
What is the current status of trial NCT04086329?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-01-17. Estimated completion is 2027-08-01.
What conditions does trial NCT04086329 study?
This clinical trial studies the following conditions: Mitochondrial Diseases, MItochondrial Myopathies.
What interventions are being tested in trial NCT04086329?
The interventions under investigation include: Nanosensor (DEVICE).
Who is sponsoring clinical trial NCT04086329?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04086329 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitochondrial Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Applying pGz in Mitochondrial Disease
RECRUITING · Phase 1
-
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
COMPLETED · Phase 1
-
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
RECRUITING
-
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
RECRUITING · Phase 3
-
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
RECRUITING
-
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.